Compagnie Lombard Odier S Cm A Apellis Pharmaceuticals, Inc. Transaction History
Compagnie Lombard Odier S Cm A
- $7.73 Billion
- Q1 2025
A detailed history of Compagnie Lombard Odier S Cm A transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Compagnie Lombard Odier S Cm A holds 11,000 shares of APLS stock, worth $201,300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,000
Previous 11,000
-0.0%
Holding current value
$201,300
Previous $351,000
31.62%
% of portfolio
0.0%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding APLS
# of Institutions
295Shares Held
124MCall Options Held
921KPut Options Held
761K-
Wellington Management Group LLP Boston, MA12.3MShares$225 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$224 Million4.32% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$218 Million20.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$185 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$176 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.01B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...